Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNPX NASDAQ:ITRM NASDAQ:KLTO NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.29+12.8%$0.23$0.14▼$3.97$8.65M-0.6523.69 million shs12.15 million shsITRMIterum Therapeutics$0.68-3.7%$0.79$0.61▼$3.02$33.44M3.04687,689 shs1.24 million shsKLTOKlotho Neurosciences$0.59-4.6%$0.93$0.11▼$3.91$37.98M10.742.71 million shs2.71 million shsPYRGFPyroGenesis Canada$0.19+11.2%$0.26$0.17▼$0.71$32.56M0.8114,627 shs2,403 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex0.00%+27.10%+35.05%-0.07%-39.22%ITRMIterum Therapeutics0.00%+0.63%-16.77%-31.12%-35.31%KLTOKlotho Neurosciences0.00%+21.67%-24.24%-63.11%+59,019,900.00%PYRGFPyroGenesis Canada0.00%+1.53%-27.33%-43.96%-66.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGenprex$0.29+12.8%$0.23$0.14▼$3.97$8.65M-0.6523.69 million shs12.15 million shsITRMIterum Therapeutics$0.68-3.7%$0.79$0.61▼$3.02$33.44M3.04687,689 shs1.24 million shsKLTOKlotho Neurosciences$0.59-4.6%$0.93$0.11▼$3.91$37.98M10.742.71 million shs2.71 million shsPYRGFPyroGenesis Canada$0.19+11.2%$0.26$0.17▼$0.71$32.56M0.8114,627 shs2,403 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGenprex0.00%+27.10%+35.05%-0.07%-39.22%ITRMIterum Therapeutics0.00%+0.63%-16.77%-31.12%-35.31%KLTOKlotho Neurosciences0.00%+21.67%-24.24%-63.11%+59,019,900.00%PYRGFPyroGenesis Canada0.00%+1.53%-27.33%-43.96%-66.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNPXGenprex 0.00N/AN/AN/AITRMIterum Therapeutics 3.00Buy$9.001,218.68% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNPXGenprexN/AN/AN/AN/A$0.15 per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/AKLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/APYRGFPyroGenesis Canada$9.14M3.96N/AN/A($0.01) per share-19.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNPXGenprex-$21.11MN/A0.00N/AN/AN/A-809.27%-386.95%11/11/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)KLTOKlotho Neurosciences-$6.15M-$0.45N/A∞N/AN/A-325.88%-242.15%N/APYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ALatest GNPX, ITRM, PYRGF, and KLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025KLTOKlotho NeurosciencesN/A-$0.12N/A-$0.12N/AN/A8/14/2025Q2 2025GNPXGenprex-$0.71-$0.17+$0.54-$0.17N/AN/A8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNPXGenprexN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNPXGenprexN/A0.840.84ITRMIterum TherapeuticsN/A2.692.52KLTOKlotho NeurosciencesN/A135.73135.73PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNPXGenprex14.05%ITRMIterum Therapeutics9.21%KLTOKlotho Neurosciences20.07%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipGNPXGenprex0.44%ITRMIterum Therapeutics2.40%KLTOKlotho Neurosciences26.70%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNPXGenprex2033.47 million33.32 millionNo DataITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableKLTOKlotho NeurosciencesN/A61.37 million44.99 millionN/APYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataGNPX, ITRM, PYRGF, and KLTO HeadlinesRecent News About These CompaniesHPQ Achieves Pilot-Scale Milestone in Commercial Fumed Silica Production, Sets Sights on Higher-Value Market SegmentSeptember 4, 2025 | markets.businessinsider.comPyroGenesis’ Latest Fumed Silica Test Results Post 3X Increase in Material Surface AreaSeptember 4, 2025 | markets.businessinsider.comPyroGenesis' Latest Fumed Silica Test Results Post 3X Increase in Material Surface AreaSeptember 4, 2025 | globenewswire.comPyroGenesis Announces Second Quarter 2025 ResultsAugust 6, 2025 | globenewswire.comPyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch TechnologyAugust 5, 2025 | globenewswire.comPyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference CallAugust 1, 2025 | globenewswire.comPyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing CompanyJuly 31, 2025 | globenewswire.comPyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed SilicaJuly 28, 2025 | globenewswire.comPyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata SteelJuly 15, 2025 | globenewswire.comPyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production CyclesJuly 8, 2025 | globenewswire.comPyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in EuropeJuly 2, 2025 | globenewswire.comPyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - MorningstarJune 29, 2025 | morningstar.comMPyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 27, 2025 | globenewswire.comPyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global SupplierJune 12, 2025 | globenewswire.comPyroGenesis Announces Extension to Term of WarrantsJune 9, 2025 | globenewswire.comHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29, 2025 | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28, 2025 | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, ITRM, PYRGF, and KLTO Company DescriptionsGenprex NASDAQ:GNPX$0.29 +0.03 (+12.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.28 -0.01 (-3.33%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Iterum Therapeutics NASDAQ:ITRM$0.68 -0.03 (-3.72%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$0.68 0.00 (-0.37%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Klotho Neurosciences NASDAQ:KLTO$0.59 -0.03 (-4.64%) As of 09/12/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.PyroGenesis Canada NASDAQ:PYRGF$0.19 +0.02 (+11.18%) As of 09/12/2025 03:06 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
